Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | VHL | P40337 | 1/20 | 0.50 |
| ▸ | ELOC | Q15369 | 1/20 | 0.50 |
| ▸ | ELOB | Q15370 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30714352 | 1.00 | KDM4E (0.58) | KDM4EHTTVHLELOCELOB | |
| SCHEMBL5956746 | 0.89 | KDM4E (0.47) | KDM4EHTTVHLELOCELOB | |
| SCHEMBL69249 | 0.85 | VHL (0.64) | KDM4EHTTVHLELOCELOB | |
| Ethylene SCHEMBL8101571 | 0.82 | VHL (0.60) | KDM4EHTTVHLELOCELOB | |
| SCHEMBL7992397 | 0.82 | KDM4E (0.48) | KDM4EHTTVHLELOCELOB | |
| SCHEMBL2594793 | 0.81 | S100A4 (0.43) | KDM4EHTTS100A4METAP1PARP10 | |
| SCHEMBL29922129 | 0.81 | S100A4 (0.43) | KDM4EHTTS100A4METAP1PARP10 | |
| SCHEMBL2223886 | 0.78 | KDM4E (0.58) | KDM4EHTTVHLELOCELOB | |
| SCHEMBL13938663 | 0.78 | KDM4E (0.58) | KDM4EHTTVHLELOCELOB | |
| SCHEMBL87314 | 0.78 | KDM4E (0.58) | KDM4EHTTVHLELOCELOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739684-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| CN-119384413-A | Anilino-pyrazole derivatives, compositions and methods thereof | 昂胜医药有限公司 | 2025-01-28 | — | — | CN | disclosed |
| WO-2025008060-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| US-20240383868-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-11-21 | — | — | US | disclosed |
| US-20240246950-A1 | Anilino-Pyrazole Derivatives, Compositions and Methods Thereof | Ensem Therapeutics (US) | 2024-07-25 | — | — | US | disclosed |
| EP-4294790-A1 | SMARCA DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| WO-2023244710-A1 | ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-5552444-A | AGONIST ACTIVITY AT SEROTONIN RECEPTORS, ANTIDEPRESSANTS | ELI LILLY AND COMPANY (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0716652-A1 | CARBOCYCLIC AND HETEROCYCLIC FUSED-RING QUINOLINECARBOXYLIC ACIDS USEFUL AS IMMUNOSUPPRESSIVE AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-06-19 | — | — | EP | disclosed |
| US-5470977-A | Serotonin 1A receptor agonists | ELI LILLY AND COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| US-5466709-A | Serotonin receptors | ELI LILLY AND COMPANY (US) | 1995-11-14 | — | — | US | disclosed |
| US-5428040-A | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-06-27 | — | — | US | disclosed |
| US-5426229-A | Treatment of sleep, sex, memory and appetite disorders depression, and anxiety; serotinin inhibitors | ELI LILLY AND COMPANY (US) | 1995-06-20 | — | — | US | disclosed |
| WO-1995006640-A1 | CARBOCYCLIC AND HETEROCYCLIC FUSED-RING QUINOLINECARBOXYLIC ACIDS USEFUL AS IMMUNOSUPPRESSIVE AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-03-09 | — | — | WO | disclosed |
| US-5286753-A | Serotonin 1a receptor agonists | ELI LILLY AND COMPANY (US) | 1994-02-15 | — | — | US | disclosed |
| CN-1059903-A | Nuclear substituted 2-amino-1,2,3,4 ,-tetraline, the amino thiochroman of the amino dihydrobenzopyrans 3-of 3- | LILLY CO ELI (US) | 1992-04-01 | — | — | CN | disclosed |
| EP-0471515-A1 | Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes, 3-aminochromanes and 3-aminothiochromanes | ELI LILLY AND COMPANY (US) | 1992-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | KDM4E 1848/4885HTT 234/4885VHL 1/4885 |
| US-20240383868-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | KDM4E 223/4885HTT 2451/4885VHL 264/4885 |
| US-20240246950-A1 | Anilino-Pyrazole Derivatives, Compositions and Methods Thereof | CDK2, CDK3, CDK4 | KDM4E 1787/4885HTT 3149/4885VHL 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.